Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of JNJ-56136379 on Biktarvy PK in Healthy Participants
NCT04853524Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bersacapavir in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of Bictegravir (BIC) and Emtricitabine (FTC), Plasma Concentration of Tenofovir Alafenamide (TAF) and 2 more. Planned start May 2021; status: withdrawn.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04853524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853524.